Orphan diseases are diseases or conditions that affect an extremely small number of individuals as compared to the general population. In the U.S., a therapeutic that treats a disease with a prevalence of 200,000 or less is referred to as an Orphan drug, while in the EU the threshold for receiving an Orphan designation is aimed at diseases that affect fewer than one in 2,000 people.  

Over the past several years, the regulatory environment in both the U.S. and EU has been relatively favorable. The rare disease space, in particular, has grown significantly with regard to the number of (1) Orphan drug designations issued by the FDA, (2) new drugs in active clinical development, and (3) approved drugs. Since the start of the decade, the pricing environment has also been largely favorable, which has enabled companies to achieve premium pricing for their Orphan drug portfolio.

Account Login


Once you register for a free online demo

 We would provide a guided tour to help you understand our offerings in detail

 You get a look and feel of our offerings even before you actually pay and subscribe with us

 Post demo once you confirm your interest & make payment ;accordingly, we initiate your annual subscription access

As you are already registered with us we generate your personalized login credentials and share with you

 The personalized login credentials allow you to access our exclusive insightful intelligence and comprehensive analytical reports for one or multiple years